Emerald Acquisition’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Emerald Acquisition’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-325	Closed	-$42K	–	3067
2016 Q2	$42K	Buy	+325	New	+$36.2K	﹤0.01%	2930

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Emerald Acquisition's BLCM Position: Q3 2016 in Review

Emerald Acquisition sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2016, closing a stake of 325 shares — an estimated $42K sold.

Emerald Acquisition first reported a position in BLCM in Q2 2016 and held it in 1 quarter. The position peaked at $42K in Q2 2016. 70 funds tracked by Wall St. Rank hold BLCM as of Q3 2016.

Emerald Acquisition reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
Emerald Acquisition sold 325 Bellicum Pharmaceuticals, Inc. shares in Q3 2016, an estimated $42K.
Emerald Acquisition first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2016 and held it in 1 quarter.
Emerald Acquisition's Bellicum Pharmaceuticals, Inc. position peaked at $42K in Q2 2016.
70 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.